Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 05:26am CET
   By Rumman Ahmed 
 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
Stocks mentioned in the article
ChangeLast1st jan.
BIOCON LTD 0.42% 627.65 End-of-day quote.15.97%
BRISTOL-MYERS SQUIBB COMPANY 3.05% 67.95 Delayed Quote.7.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
02/24Big pharma could turn to viruses to boost cancer immunotherapies
AQ
02/23BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb Co. Describe Advan..
AQ
02/23BRISTOL MYERS SQUIBB : Research Conducted at Bristol-Myers Squibb Has Updated Ou..
AQ
02/23BRISTOL MYERS SQUIBB : and Nektar Therapeutics Announce Global Development & Com..
AQ
02/23Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Br..
BU
02/23BRISTOL MYERS SQUIBB : Demonstrates Their Commitment to Site Relationships by Jo..
AQ
02/22THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
BU
02/22Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 fr..
BU
02/21BRISTOL MYERS SQUIBB : Why dozens of lawsuits against diabetes drug are coming t..
AQ
02/21THE KLEIN LAW FIRM : Notifies Investors of an Investigation Concerning Possible ..
BU
More news
News from SeekingAlpha
02/25THE NO BS PLAN : Week 2 Report - The Advaxis Apocalypse Is Nigh? 
02/23Arcus Biosciences Files To Raise $100 Million In IPO 
02/21Bristol-Myers Squibb Sows Confusion 
02/20BRISTOL-MYERS SQUIBB : Next Stop, Record Levels 
02/20Nektar And Bristol-Myers Squibb's Deal Could Be An Opportunity For NewLink 
Financials ($)
Sales 2018 21 689 M
EBIT 2018 5 672 M
Net income 2018 5 211 M
Finance 2018 852 M
Yield 2018 2,46%
P/E ratio 2018 21,90
P/E ratio 2019 18,58
EV / Sales 2018 4,98x
EV / Sales 2019 4,50x
Capitalization 109 B
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 65,1 $
Spread / Average Target -2,1%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY7.60%108 890
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
MERCK AND COMPANY-3.02%148 618